AREV Life Sciences Global Corp.
AREV
CNSX
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Net Income | 88.29% | 85.15% | 68.92% | -85.28% | -5.61% |
| Total Depreciation and Amortization | -58.63% | -60.69% | -58.20% | -24.82% | -15.31% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -97.35% | -99.69% | -20.96% | 68.67% | 103.08% |
| Change in Net Operating Assets | -95.42% | -102.88% | -78.35% | 114.85% | 48.46% |
| Cash from Operations | -163.64% | 13.80% | 85.34% | 95.18% | 117.37% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | 4.72% | -- |
| Cash from Investing | -- | -- | -- | 99.70% | 100.00% |
| Total Debt Issued | -100.00% | -- | 554.00% | -102.74% | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -100.00% | -43.04% | -100.00% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 100.00% | -40.02% | 28.73% | -101.14% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | 100.00% | -100.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -240.00% | -347.17% | 126.17% | -110.68% | 106.28% |
